Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STR-P004 in Immune-Mediated Kidney Diseases
NCT07363954Phase 1Not yet recruiting
- Sponsor
- Starna Therapeutics
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
01
Overview
Phase 1, open-label, single-arm trial of STR-P004 in systemic lupus erythematosus (SLE), lupus nephritis (LN), Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and 5 more, sponsored by Starna Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 3 months, Serious Adverse Events at 3 months and 1 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
STR-P004
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)anti-neutrophil cytoplasmic antibody-associated glomerulonephritisanti-glomerular basement membrane disease
Beyond the preview
Go deeper on NCT07363954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07363954.